We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP20588
Abstract: The Good Manufacturing Practice (GMP) state that the active pharmaceutical ingredient (API) intended for use in early stage clinical trials should be of "suitable" quality. The Clinic Ready quality standard ensures that the API is synthesised with all the appropriate documentation to facilitate QP release of the final IMP for guman clinical dosing.
Summary: The Good Manufacturing Practice (GMP) state that the active pharmaceutical ingredient (API) intended for use in early stage clinical trials should be of "suitable" quality. The Clinic Ready quality standard ensures that the API is synthesised with all the appropriate documentation to facilitate QP release of the final IMP for guman clinical dosing.
Summary: The Good Manufacturing Practice (GMP) state that the active pharmaceutical ingredient (API) intended for use in early stage clinical trials should be of "suitable" quality. The Clinic Ready quality standard ensures that the API is synthesised with all the appropriate documentation to facilitate QP release of the final IMP for guman clinical dosing.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
Comparison Of Different Approaches To Generate Virtual Patient Populations Of Different Sizes For QSP Model Of Erythropoiesis
Galina Kolesova, Oleg Demin, Alexander Stepanov
The QSP model of amyloid beta and tau oligomers influence on synaptic plasticity
Stepan Lerner, Tatiana Karelina
BOC Sciences New Promotes: Peptides for Functional Cosmetics R&D
Alex Brown
An Overview of PseudoUridine Modification in RNAs
Alex Brown
An Overview of Mainstream Carbohydrates in the Market
Alex Brown
